Clinical Trials Logo
  1. Home
  2. C3 Glomerulopathy
  3. NCT03459443

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

C3 Glomerulopathy Clinical Trial

Official title:
An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471

Clinical Trial Summary

The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.

Clinical Trial Description

This was an open-label study to evaluate the efficacy of treatment with danicopan in participants 12 years of age or older with biopsy-confirmed C3G or IC-MPGN who had not undergone renal transplantation. All participants were to receive active treatment with danicopan for approximately 40 months. The starting dosage was to be 100 mg TID, and after 2 weeks, the dosage was to be increased to 200 mg TID for participants with body weight ≥ 60 kg or 150 mg TID for participants with body weight < 60 kg. Planned enrollment was approximately 20 participants. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03459443
Study type Interventional
Source Alexion
Contact
Status Terminated
Phase Phase 2
Start date June 20, 2018
Completion date March 29, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03955445 - Long-term Efficacy, Safety and Tolerability of LNP023 in C3G Phase 3
Recruiting NCT04183101 - Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Not yet recruiting NCT05647811 - Study of NM8074 in Adult C3 Glomerulopathy Patients Phase 1/Phase 2
Active, not recruiting NCT05067127 - Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Active, not recruiting NCT05809531 - An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Recruiting NCT06209736 - Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN Phase 2
Completed NCT03369236 - A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Phase 2
Active, not recruiting NCT04572854 - Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Phase 2
Recruiting NCT02682407 - Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Phase 2
Recruiting NCT05083364 - Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease Phase 1
Completed NCT03723512 - Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study N/A
Completed NCT03124368 - A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Phase 2
Available NCT04729062 - C3G/Primary IC-MPGN EAP